While mammalian target of rapamycin inhibitors (mTORis) reduce AML volume, long-term real-world data on clinically meaningful bleeding and procedure outcomes remain limited, particularly in cohorts enriched for high-risk imaging phenotypes.<h4>Methods</h4>We conducted a multicentre observational study (2004-2020) in three French tertiary centres. Here, MTOR is linked to acute myeloid leukemia.